The approval is based on a phase 2 trial showing that Libtayo achieved a response in 29% of patients ... although the picture may not be quite so simple. On its own, Keytruda cut the risk of ...

with a duration of response of 16 months versus seven months, respectively. Libtayo – the sixth PD-L/PD-L1 inhibitor to reach the market – is already approved to treat newly-diagnosed advanced ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and ...